Clinical Efficacy of Leflunomide Combined with Moderate Dose Prednisone in Treatment of IgA Nephropathy and Effects on Serum Levels of ICAM-1 MCP-1 and TGF-β1
ZHAO Jing'an, JI Yan
Jingzhou Second People's Hospital, Hubei Jingzhou 434000, China
Abstract：Objective: To investigate the effect of leflunomide combined with moderate doses of prednisone in the treatment of IgA nephropathy (Immunoglobulin A nephropathy) the clinical effect of serum intercellular adhesion molecule -1 (ICAM-1 intercellular adhesion molecule-1), monocyte chemoattractant protein -1 (monocyte chemotactic protein 1, MCP-1), transformation growth factor beta 1 (transforming growth factor beta TGF- 1, β1). Methods: 96 patients with IgA nephropathy admitted to our hospital from October 2013 to May 2016 were randomly divided into control group and experimental group, with 48 cases in each group. All patients on admission were treated with conventional treatment. On the basis of this treatment, the control group received a large dose of prednisone, and the experimental group received leflunomide and a medium dose of prednisone.The clinical efficacy of the two groups before and after treatment was observed and compared. The levels of serum ICAM-1, MCP-1, TGF-β1, adverse reactions were observed in the two groups. Results: After treatment, the effective rate of the experimental group (95.83%) was higher than that of the control group (81.25%), and the difference was statistically significant (P<0.05). 3 months and 6 months after treatment, the levels of serum ICAM-1, MCP-1 and TGF-β1 were significantly decreased in the two groups, and the experimental group was significantly lower than that of the control group. There was a significant difference in the interaction between the two groups, different points and between groups and at the same time (P<0.05). There was no significant difference in adverse reactions between the two groups (P>0.05). Conclusion: The effect of leflunomide and moderate dosage of prednisone in the treatment of IgA nephropathy is sure to reduce the level of serum ICAM-1, MCP-1 and TGF-β1, which is worthy of clinical application.
赵敬安, 纪燕. 来氟米特联合中等剂量泼尼松治疗IgA肾病的临床疗效及对血清ICAM-1 MCP-1 TGF-β1的影响[J]. 河北医学, 2018, 24(6): 914-917.
ZHAO Jing'an, JI Yan. Clinical Efficacy of Leflunomide Combined with Moderate Dose Prednisone in Treatment of IgA Nephropathy and Effects on Serum Levels of ICAM-1 MCP-1 and TGF-β1. HeBei Med, 2018, 24(6): 914-917.
2018, Vol. 24 
冀公网安备13080202000677号